Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.59 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.49 |
| ▸ | GRK2 | P25098 | 1/20 | 0.47 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264228 | 0.91 | MMP13 (0.57) | MMP13IDO1HSD17B13GRK2SLC2A1 | |
| SCHEMBL263249 | 0.91 | MMP13 (0.57) | MMP13SLC2A1EPHX2PPARGLMNA | |
| SCHEMBL4550084 | 0.79 | HDAC6 (0.58) | MMP13SLC2A1 | |
| SCHEMBL262559 | 0.79 | LMNA (0.52) | MMP13HSD17B13SLC2A1PPARGLMNA | |
| SCHEMBL2312467 | 0.79 | MMP13 (0.64) | MMP13IDO1 | |
| SCHEMBL264076 | 0.77 | MAPK1 (0.52) | MMP13HSD17B13SLC2A1PPARGLMNA | |
| SCHEMBL2314293 | 0.77 | MMP13 (0.61) | MMP13IDO1SLC2A1PPARG | |
| SCHEMBL2315445 | 0.77 | SCD (0.63) | MMP13IDO1SLC2A1PPARG | |
| SCHEMBL6272899 | 0.74 | MMP13 (1.00) | MMP13 | |
| SCHEMBL3928231 | 0.73 | THRB (0.68) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133998-B2 | Bicyclic pyrimidine derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2012-03-13 | — | — | US | disclosed |
| WO-2008138126-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280900-A1 | BICYCLIC PYRIMIDINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1G, RYR1 | MMP13 4849/4885IDO1 2339/4885HSD17B13 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.